Caribou Biosciences Stock Today
| CRBU Stock | USD 1.00 0.05 5.25% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Caribou Biosciences is selling for under 0.99989998 as of the 20th of March 2025; that is 5.25 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.95. Caribou Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of July 2021 | Category Healthcare | Classification Health Care |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. The company was incorporated in 2011 and is headquartered in Berkeley, California. The company has 93 M outstanding shares of which 8.91 M shares are currently shorted by private and institutional investors with about 7.92 trading days to cover. More on Caribou Biosciences
Moving together with Caribou Stock
Moving against Caribou Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Caribou Stock Highlights
| Old Name | Multi Units Luxembourg- Lyxor Commodities Thomson Reuters/Corecommodity Crb Tr Ucits Etf | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsCaribou Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Caribou Biosciences' financial leverage. It provides some insight into what part of Caribou Biosciences' total assets is financed by creditors.
| |||||
Caribou Biosciences (CRBU) is traded on NASDAQ Exchange in USA. It is located in 2929 7th Street, Berkeley, CA, United States, 94710 and employs 147 people. Caribou Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 88.44 M. Caribou Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 93 M outstanding shares of which 8.91 M shares are currently shorted by private and institutional investors with about 7.92 trading days to cover.
Caribou Biosciences currently holds about 339.92 M in cash with (138.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Caribou Biosciences Probability Of Bankruptcy
Ownership AllocationCaribou Biosciences holds a total of 93 Million outstanding shares. Over half of Caribou Biosciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Caribou Ownership Details
Caribou Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.7 M | |
| State Street Corp | 2024-12-31 | 1.7 M | |
| Fmr Inc | 2024-12-31 | 1.6 M | |
| Two Sigma Advisers, Llc | 2024-12-31 | 1.5 M | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 1.2 M | |
| Two Sigma Investments Llc | 2024-12-31 | 1.1 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 1.1 M | |
| Point72 Asset Management, L.p. | 2024-12-31 | 1 M | |
| Fidelity International Ltd | 2024-12-31 | 860.7 K | |
| Blackrock Inc | 2024-12-31 | 6.6 M | |
| Pfizer Inc | 2024-12-31 | 4.7 M |
Caribou Biosciences Historical Income Statement
Caribou Stock Against Markets
Caribou Biosciences Corporate Management
| Sriram MBA | Chief Officer | Profile | |
| Amy CFA | Vice Communications | Profile | |
| Cindy Hayashi | VP HR | Profile | |
| Ryan Fischesser | Interim Controller | Profile | |
| Jason MBA | Chief Officer | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Timothy MBA | Chief Officer | Profile |
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.